LOTCOL Study: Local Treatment of Colo-rectal Liver Met

Inclusion Criteria: * Histologically verified adenocarcinoma of colon or rectum * Ambulatory with an ECOG performance status 0-2 * At least 18 years of age * Non-resectable liver metastases * Progressive disease on or within 4 months after 1.line chemotherapy for KRAS mutant or after 2.line chemotherapy in KRAS wild type patients * 1-4 liver metastases with largest diameter of up to 6 cm on CT-scan * Up to 20 lesions in liver with no more than 4 lesions larger than 4 cm * The patients will start 2./3. line chemotherapy (KRAS mutant/KRAS wt) * Laboratory values as the following: * ANC ³ 1.5 x 109/L * Platelets ³ 100 x 109/L * Hb ³ 9g/dL * Creatinine £ 2x upper limit of normal * Bilirubin \< 2.0x the upper limit of normal * ASAT and ALAT £ 5x the upper limit of normal * Albumin levels \> 30 g/L * INR\<1.3 * Signed informed consent and expected cooperation of the patients for the treatment and follow up must be obtained and documented according to ICH GCP, and national/local regulations Exclusion Criteria: * Previous treatment with 2. or 3. line chemotherapy (KRAS mutant/KRAS wt) * History of prior metastatic disease the last 3 years * History of CNS or bone metastases * Significant cardiac or other medical illness that would limit activity or survival, such as severe congestive heart failure, unstable angina, or serious cardiac arrhythmia * Largest liver mets \>6 cm, more than 4 liver lesions \>4 cm * Pulmonary mets\>3 cm * Lymph node mets \>2.5 cm * Chemotherapy/radiation therapy or major surgery within the last 4 weeks before start of treatment * Any reason why, in the opinion of the investigator, the patient should not participate.